查看購物車
  • Simplified Chinese
  • English
封面
市場調查報告書
商品編碼
1712540

全球生物可吸收植入物市場 - 2025-2033

Global Bioresorbable Implants Market - 2025-2033
出版日期: | 出版商: DataM Intelligence | 英文 180 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

2024 年全球生物可吸收植入物市場規模達到 70 億美元，預計到 2033 年將達到 143.4 億美元，在 2025-2033 年預測期內的複合年成長率為 7.4%。

生物可吸收植入物是由特殊設計的聚合物製成的醫療器械，這些聚合物會隨著時間的推移在體內自然溶解或分解，因此在完成功能後無需進行手術移除。這些植入物由疏水或親水性聚合物組成，旨在支持各種醫療應用中的癒合過程，特別是手術後的癒合過程。

它們具有多種形式，常用於骨科手術、組織修復和藥物傳輸系統。隨著生物可吸收植入物逐漸分解為可被人體安全吸收或排泄的無毒副產品，它們提供了一種比永久性植入物侵入性更小、對患者更友好的替代方案，從而降低了長期併發症的風險和額外手術的需要。

市場動態：

駕駛員和約束裝置

採用創新材料的先進植入物正在蓬勃發展

利用創新材料的植入物的不斷發展極大地推動了生物可吸收植入物市場的成長。材料科學的進步導致了可生物吸收的聚合物和複合材料的產生，這些聚合物和複合材料具有更高的機械強度、生物相容性和可控制的分解率。例如，將生物活性玻璃和鎂基合金融入植入物設計中，增強了其功能和癒合能力。

這些創新使得植入物的發展不僅能支持癒合，還能促進組織再生，進而擴大其在各個醫學專業的應用。 2025年1月，可吸收骨科植入物的先驅Bioretec已完成其CE標誌核准流程，並可在歐盟和承認CE標誌市場授權的非歐洲國家開始商業化其RemeOs創傷螺絲產品組合。此項全面批准涵蓋所有管狀和非管狀產品設計，尺寸範圍從直徑 2.0 毫米至 4.0 毫米，長度從 8 毫米至 50 毫米。核准的適應症包括使用這些螺絲釘對成人和兒童患者的上肢和下肢（手和前腳除外）進行骨折和錯位固定。

此外，將感測器和藥物傳輸系統等智慧技術融入生物可吸收植入物中，可實現即時監測和針對性治療，進一步改善患者的治療效果。這些技術進步使生物可吸收植入物更加有效和多功能，從而加速其在臨床環境中的應用。

設計和製造成本高

設計和製造生物可吸收植入物的成本高昂仍然是市場更廣泛採用的主要障礙。這些植入物需要先進的材料、專門的生產技術以及廣泛的研究和測試，以確保生物相容性和精確的分解率。 3D 列印、聚合物共混和表面改質等製程需要精密的設備和熟練的勞動力，所有這些都大大增加了生產成本。

目錄

第1章：市場介紹和範圍

  • 報告目標
  • 報告範圍和定義
  • 報告範圍

第2章：高階主管見解與關鍵要點

  • 市場亮點和戰略要點
  • 主要趨勢和未來預測
  • 依材料類型分類
  • 按應用程式截取的程式碼片段
  • 最終用戶的程式碼片段
  • 按地區分類

第3章：動態

  • 影響因素
    • 驅動程式
      • 批准數量不斷增加
      • 創新材料植入物的發展日新月異
    • 限制
      • 設計和製造成本高
      • 醫療專業人員的認知度有限
    • 機會
      • 轉向微創和以患者為中心的醫療保健解決方案
    • 影響分析

第4章：戰略洞察與產業展望

  • 市場領導者和先驅者
    • 新興先鋒和傑出參與者
    • 擁有最大銷售品牌的成熟領導者
    • 擁有成熟產品的市場領導者
  • CXO 觀點
  • 最新進展與突破
  • 案例研究/正在進行的研究
  • 監管和報銷情況
    • 北美洲
    • 歐洲
    • 亞太地區
    • 南美洲
    • 中東和非洲
  • 波特五力分析
  • 供應鏈分析
  • 專利分析
  • SWOT分析
  • 未滿足的需求和差距
  • 市場進入和擴張的推薦策略
  • 情境分析：最佳情況、基本情況和最壞情況預測
  • 定價分析和價格動態
  • 關鍵意見領袖

第5章：生物可吸收植入物市場（依材料類型）

  • 金屬
  • 聚合物
  • PLGA-聚乳酸-羥基乙酸共聚物
  • PLLA-聚L-乳酸
  • PGA-聚乙醇酸
  • PLA-聚乳酸
  • 其他

第6章：生物可吸收植入物市場（依應用）

  • 心血管
  • 骨科
  • 其他

第7章：生物可吸收植入物市場（依最終用戶分類）

  • 醫院
  • 門診手術中心
  • 其他

第8章：生物可吸收植入物市場，依區域市場分析與成長機會

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 西班牙
    • 義大利
    • 歐洲其他地區
  • 南美洲
    • 巴西
    • 阿根廷
    • 南美洲其他地區
  • 亞太
    • 中國
    • 印度
    • 日本
    • 韓國
    • 亞太其他地區
  • 中東和非洲

第9章：競爭格局與市場定位

  • 競爭概況和主要市場參與者
  • 市佔率分析與定位矩陣
  • 策略夥伴關係、併購
  • 產品組合和創新的關鍵發展
  • 公司基準化分析

第10章：公司簡介

  • Bioretec Ltd
    • 公司概況
    • 產品組合
      • 產品描述
      • 產品關鍵績效指標 (KPI)
      • 歷史和預測產品銷售
      • 產品銷售量
    • 財務概覽
      • 公司收入
      • 地區收入佔有率
      • 收入預測
    • 關鍵進展
      • 併購
      • 關鍵產品開發活動
      • 監管部門批准等
    • SWOT分析
  • Stryker Corporation
  • CONMED Corporation
  • Syntellix AG
  • Johnson & Johnson Medical Devices (DePuy Synthes)
  • Zimmer Biomet
  • NuVasive Inc.
  • KLS Martin Group
  • Smith+Nephew
  • Evonik Industries AG
  • indicates "similar data will be provided for each market player."

第 11 章：假設與研究方法

  • 資料收集方法
  • 數據三角測量
  • 預測技術
  • 數據驗證和確認

第 12 章：附錄

簡介目錄
Product Code: MD887

The global bioresorbable implants market reached US$ 7.00 billion in 2024 and is expected to reach US$ 14.34 billion by 2033, growing at a CAGR of 7.4% during the forecast period 2025-2033.

Bioresorbable implants are medical devices made from specially engineered polymers that naturally dissolve or degrade within the body over time, eliminating the need for surgical removal once their function is complete. These implants are composed of either hydrophobic or hydrophilic polymers and are designed to support healing processes in various medical applications, particularly after surgery.

They are available in a wide range of forms and are commonly used in orthopedic procedures, tissue repair, and drug delivery systems. As they gradually break down into non-toxic byproducts that are safely absorbed or excreted by the body, bioresorbable implants offer a less invasive, patient-friendly alternative to permanent implants, reducing the risk of long-term complications and the need for additional surgeries.

Market Dynamics: Drivers & Restraints

Rising Development of Advanced Implants with Innovative Materials

The rising development of implants utilizing innovative materials is significantly driving the growth of the bioresorbable implants market. Advancements in material science have led to the creation of bioresorbable polymers and composites that offer improved mechanical strength, biocompatibility, and controlled degradation rates. For instance, the integration of bioactive glass and magnesium-based alloys into implant designs has enhanced their functionality and healing capabilities.

These innovations enable the development of implants that not only support healing but also promote tissue regeneration, thereby expanding their applications across various medical specialties. In January 2025, Bioretec, a pioneer in absorbable orthopedic implants, has completed its CE mark approval process and can start commercialization of its RemeOs Trauma Screw product portfolio within the European Union and non-European countries that recognize the CE mark market authorization. This comprehensive approval covers all cannulated and non-cannulated product designs, with sizes ranging from diameters of 2.0mm to 4.0mm and lengths from 8mm to 50mm. Indications approved include the use of these screws for fracture and malalignment fixations in both upper and lower extremities of adult and pediatric patients, excluding the hand and forefoot.

Additionally, the incorporation of smart technologies, such as sensors and drug delivery systems, into bioresorbable implants allows for real-time monitoring and targeted treatment, further enhancing patient outcomes. These technological advancements are making bioresorbable implants more effective and versatile, thereby accelerating their adoption in clinical settings.

High Cost of Designing and Manufacturing

The high cost of designing and manufacturing bioresorbable implants remains a major barrier to the market's broader adoption. These implants require advanced materials, specialized production techniques, and extensive research and testing to ensure biocompatibility and precise degradation rates. Processes like 3D printing, polymer blending, and surface modification demand sophisticated equipment and skilled labor, all of which significantly drive up production costs.

Segment Analysis

The global bioresorbable implants market is segmented based on material type, application, and end-user region.

Material Type:

PLGA (Poly lactic-co-glycolic acid) in the material type segment is expected to dominate the bioresorbable implants market.

PLGA (Poly lactic-co-glycolic acid) is expected to dominate the bioresorbable implants market due to its exceptional versatility, safety profile, and broad range of clinical applications. As a copolymer of lactic acid and glycolic acid, PLGA offers customizable degradation rates by simply altering the ratio of its two components, allowing it to be tailored for everything from short-term tissue scaffolds to longer-term orthopedic or cardiovascular support. Its biocompatibility and non-toxic degradation byproducts (carbon dioxide and water) make it ideal for implantation, with minimal risk of inflammation or rejection.

PLGA is already widely used in FDA-approved medical devices, including sutures, screws, pins, and drug-delivery systems, which has established a strong regulatory precedent for new product approvals. Moreover, PLGA's role in controlled drug release has expanded its utility beyond just structural support. Given its proven track record, ease of processing, and adaptability across various specialties like orthopedics, cardiology, and regenerative medicine, the PLGA segment is well-positioned to remain a leading force in the global bioresorbable implants market.

Geographical Analysis

North America is expected to dominate the global bioresorbable implants market.

North America is expected to dominate the bioresorbable implants market due to rising surgical volumes, growing adoption of advanced medical technologies, and increasing demand for patient-friendly treatment options. The region, particularly the United States, has seen a steady rise in procedures such as orthopedic repairs, soft tissue reconstruction, and cardiovascular interventions.

For instance, according to the American College of Rheumatology, in 2024, about 790,000 total knee replacements and 544,000 hip replacements were done every year in the U.S. This number continues to grow as our population ages. This increase in the number of procedures is expected to increase the demand for bioresorbable implants, as a large number of individuals in the region are hesitating about the removal surgery of implants.

Additionally, a strong focus on reducing long-term complications and avoiding secondary surgeries has led to higher acceptance of bioresorbable devices like screws, pins, and plates. Recent product approvals, such as magnesium-based bioresorbable implants, and growing use of materials like PLGA and PLLA further support this trend.

With a well-established regulatory pathway and a high level of awareness among healthcare providers, North America is expected to maintain its leading position in the global bioresorbable implants market. For instance, In March 2023, Bioretec Ltd received the market authorization of the U.S. Food and Drug Administration (FDA) for its pioneering RemeOs trauma screw to be used for healing of bone fractures aligned with the clinical trial.

Competitive Landscape

The global market players in the bioresorbable implants market include Bioretec Ltd, Stryker Corporation, CONMED Corporation, Syntellix AG, Johnson & Johnson Medical Devices (DePuy Synthes), Zimmer Biomet, NuVasive Inc., KLS Martin Group, Smith+Nephew, Evonik Industries AG, among others.

Why Purchase the Report?

  • Pipeline & Innovations: Reviews ongoing clinical trials, product pipelines, and forecasts upcoming pharmaceutical advancements.
  • Type Performance & Market Positioning: Analyzes product performance, market positioning, and growth potential to optimize strategies.
  • Real-World Evidence: Integrates patient feedback and data into product development for improved outcomes.
  • Physician Preferences & Health System Impact: Examines healthcare provider behaviors and the impact of health system mergers on adoption strategies.
  • Market Updates & Industry Changes: Covers recent regulatory changes, new policies, and emerging technologies.
  • Competitive Strategies: Analyzes competitor strategies, market share, and emerging players.
  • Pricing & Market Access: Reviews pricing models, reimbursement trends, and market access strategies.
  • Market Entry & Expansion: Identifies optimal strategies for entering new markets and partnerships.
  • Regional Growth & Investment: Highlights high-growth regions and investment opportunities.
  • Supply Chain Optimization: Assesses supply chain risks and distribution strategies for efficient Type delivery.
  • Sustainability & Regulatory Impact: Focuses on eco-friendly practices and evolving regulations in healthcare.
  • Post-market Surveillance: Uses post-market data to enhance product safety and access.
  • Pharmacoeconomics & Value-Based Pricing: Analyzes the shift to value-based pricing and data-driven decision-making in R&D.

The global bioresorbable implants market report will provide approximately 45 tables, 46 figures, and 180 pages.

Target Audience 2024

  • Manufacturers: Pharmaceutical, Biotech Companies, Contract Manufacturers, Distributors, Hospitals.
  • Regulatory & Policy: Compliance Officers, Government, Health Economists, Market Access Specialists.
  • Technology & Innovation: R&D Professionals, Clinical Trial Managers, Pharmacovigilance Experts.
  • Investors: Healthcare Investors, Venture Fund Investors, Pharma Marketing & Sales.
  • Consulting & Advisory: Healthcare Consultants, Industry Associations, Analysts.
  • Supply Chain: Distribution and Supply Chain Managers.
  • Consumers & Advocacy: Patients, Advocacy Groups, Insurance Companies.
  • Academic & Research: Academic Institutions.

Table of Contents

1. Market Introduction and Scope

  • 1.1. Objectives of the Report
  • 1.2. Report Coverage & Definitions
  • 1.3. Report Scope

2. Executive Insights and Key Takeaways

  • 2.1. Market Highlights and Strategic Takeaways
  • 2.2. Key Trends and Future Projections
  • 2.3. Snippet by Material Type
  • 2.4. Snippet by Application
  • 2.5. Snippet by End-User
  • 2.6. Snippet by Region

3. Dynamics

  • 3.1. Impacting Factors
    • 3.1.1. Drivers
      • 3.1.1.1. Rising Number of Approvals
      • 3.1.1.2. Rising Development of Implants with Innovative Materials
    • 3.1.2. Restraints
      • 3.1.2.1. High Cost of Designing and Manufacturing
      • 3.1.2.2. Limited Awareness Among Healthcare Professionals
    • 3.1.3. Opportunity
      • 3.1.3.1. Shift Toward Minimally Invasive and Patient-centric Healthcare Solutions
    • 3.1.4. Impact Analysis

4. Strategic Insights and Industry Outlook

  • 4.1. Market Leaders and Pioneers
    • 4.1.1. Emerging Pioneers and Prominent Players
    • 4.1.2. Established leaders with largest selling Brand
    • 4.1.3. Market leaders with established Product
  • 4.2. CXO Perspectives
  • 4.3. Latest Developments and Breakthroughs
  • 4.4. Case Studies/Ongoing Research
  • 4.5. Regulatory and Reimbursement Landscape
    • 4.5.1. North America
    • 4.5.2. Europe
    • 4.5.3. Asia Pacific
    • 4.5.4. South America
    • 4.5.5. Middle East & Africa
  • 4.6. Porter's Five Force Analysis
  • 4.7. Supply Chain Analysis
  • 4.8. Patent Analysis
  • 4.9. SWOT Analysis
  • 4.10. Unmet Needs and Gaps
  • 4.11. Recommended Strategies for Market Entry and Expansion
  • 4.12. Scenario Analysis: Best-Case, Base-Case, and Worst-Case Forecasts
  • 4.13. Pricing Analysis and Price Dynamics
  • 4.14. Key Opinion Leaders

5. Bioresorbable Implants Market, By Material Type

  • 5.1. Introduction
    • 5.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Material Type
    • 5.1.2. Market Attractiveness Index, By Material Type
  • 5.2. Metallic*
    • 5.2.1. Introduction
    • 5.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 5.3. Polymers
  • 5.4. PLGA- Poly lactic-co-glycolic acid
  • 5.5. PLLA- Poly L-lactide
  • 5.6. PGA- Polyglycolic Acid
  • 5.7. PLA- Polylactic Acid
  • 5.8. Others

6. Bioresorbable Implants Market, By Application

  • 6.1. Introduction
    • 6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 6.1.2. Market Attractiveness Index, By Application
  • 6.2. Cardiovascular*
    • 6.2.1. Introduction
    • 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 6.3. Orthopedics
  • 6.4. Others

7. Bioresorbable Implants Market, By End-User

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 7.1.2. Market Attractiveness Index, By End-User
  • 7.2. Hospitals*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 7.3. Ambulatory Surgical Centers
  • 7.4. Others

8. Bioresorbable Implants Market, By Regional Market Analysis and Growth Opportunities

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 8.1.2. Market Attractiveness Index, By Region
  • 8.2. North America
    • 8.2.1. Introduction
    • 8.2.2. Key Region-Specific Dynamics
    • 8.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Material Type
    • 8.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 8.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 8.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 8.2.6.1. U.S.
      • 8.2.6.2. Canada
      • 8.2.6.3. Mexico
  • 8.3. Europe
    • 8.3.1. Introduction
    • 8.3.2. Key Region-Specific Dynamics
    • 8.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Material Type
    • 8.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 8.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 8.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 8.3.6.1. Germany
      • 8.3.6.2. U.K.
      • 8.3.6.3. France
      • 8.3.6.4. Spain
      • 8.3.6.5. Italy
      • 8.3.6.6. Rest of Europe
  • 8.4. South America
    • 8.4.1. Introduction
    • 8.4.2. Key Region-Specific Dynamics
    • 8.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Material Type
    • 8.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 8.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 8.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 8.4.6.1. Brazil
      • 8.4.6.2. Argentina
      • 8.4.6.3. Rest of South America
  • 8.5. Asia-Pacific
    • 8.5.1. Introduction
    • 8.5.2. Key Region-Specific Dynamics
    • 8.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Material Type
    • 8.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 8.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 8.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 8.5.6.1. China
      • 8.5.6.2. India
      • 8.5.6.3. Japan
      • 8.5.6.4. South Korea
      • 8.5.6.5. Rest of Asia-Pacific
  • 8.6. Middle East and Africa
    • 8.6.1. Introduction
    • 8.6.2. Key Region-Specific Dynamics
    • 8.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Material Type
    • 8.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 8.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User

9. Competitive Landscape and Market Positioning

  • 9.1. Competitive Overview and Key Market Players
  • 9.2. Market Share Analysis and Positioning Matrix
  • 9.3. Strategic Partnerships, Mergers & Acquisitions
  • 9.4. Key Developments in Product Portfolios and Innovations
  • 9.5. Company Benchmarking

10. Company Profiles

  • 10.1. Bioretec Ltd*
    • 10.1.1. Company Overview
    • 10.1.2. Product Portfolio
      • 10.1.2.1. Product Description
      • 10.1.2.2. Product Key Performance Indicators (KPIs)
      • 10.1.2.3. Historic and Forecasted Product Sales
      • 10.1.2.4. Product Sales Volume
    • 10.1.3. Financial Overview
      • 10.1.3.1. Company Revenue
      • 10.1.3.2. Geographical Revenue Shares
      • 10.1.3.3. Revenue Forecasts
    • 10.1.4. Key Developments
      • 10.1.4.1. Mergers & Acquisitions
      • 10.1.4.2. Key Product Development Activities
      • 10.1.4.3. Regulatory Approvals, etc.
    • 10.1.5. SWOT Analysis
  • 10.2. Stryker Corporation
  • 10.3. CONMED Corporation
  • 10.4. Syntellix AG
  • 10.5. Johnson & Johnson Medical Devices (DePuy Synthes)
  • 10.6. Zimmer Biomet
  • 10.7. NuVasive Inc.
  • 10.8. KLS Martin Group
  • 10.9. Smith+Nephew
  • 10.10. Evonik Industries AG
  • indicates "similar data will be provided for each market player."

LIST NOT EXHAUSTIVE

11. Assumption and Research Methodology

  • 11.1. Data Collection Methods
  • 11.2. Data Triangulation
  • 11.3. Forecasting Techniques
  • 11.4. Data Verification and Validation

12. Appendix

  • 12.1. About Us and Services
  • 12.2. Contact Us